Recently, the multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial of LW402 for the evaluation of efficacy and safety in patients with moderate-to-severe atopic dermatitis （AD） has successfully enrolled its first patient. Sponsored by LWBP, this trial is led by Professor Jianzhong Zhang and Professor Cheng Zhou from Peking University People’s Hospital.
AD is a chronic, recurrent autoimmune skin disease characterized by local or systemic abnormal inflammatory and immune responses. It manifests clinically as severe pruritus, dry skin, erythema, papules, and other symptoms, which severely impair patients’ quality of life.
LW402 is a next-generation highly selective JAK1 inhibitor independently developed by LWBP, intended for the treatment of multiple autoimmune diseases including atopic dermatitis, rheumatoid arthritis, vitiligo and etc. Existing clinical data demonstrate that LW402 has a rapid onset of action, with significant improvements in patient inflammation-related efficacy endpoints observed as early as one week. There was no statistical difference in the total incidence of adverse events among the placebo and treatment groups, supporting excellent efficacy and safety profiles with long-term use features.